A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice

Molecular Therapy

Volumn 20, Issue 12, 2012, Pages 2222-2233

  Lopez, M Veronica ^a   Rivera, Angel A ^b   Viale, Diego L ^a   Benedetti, Lorena ^a   Cuneo, Nicasio ^c   Kimball, Kristopher J ^d   Wang, Minghui ^b   Douglas, Joanne T ^b   Zhu, Zeng B ^b   Bravo, Alicia I ^e   Gidekel, Manuel ^f   Alvarez, Ronald D ^d   Curiel, David T ^b   Podhajcer, Osvaldo L ^a  

^a IIBBA CONICET ^*  (Argentina)

^b Division of Human Gene Therapy   (United States)

^c Hospital Maria Curie   (Argentina)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Hospital Eva Peron   (Argentina)

^f UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; E1A PROTEIN; MESSENGER RNA; ONCOLYTIC ADENOVIRUS; OSTEONECTIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; E1A GENE; EX VIVO STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIMARY TUMOR; PROTEIN EXPRESSION; SECRETED PROTEIN ACIDIC RICH IN CYSTEINE GENE; TUMOR XENOGRAFT; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 84870577541     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.147     Document Type: Article

References (45)

1. Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J, Murray, T et al. (2008). Cancer statistics, 2008.CA Cancer J Clin 58: 71-96.
2. .Matthews, KS, Alvarez, RD and Curiel, DT (2009). Advancements in adenoviral based virotherapy for ovarian cancer. Adv Drug Deliv Rev 61: 836-841.
3. .Riman, T, Nilsson, S and Persson, IR (2004). Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 83: 783-795.
4. .Alemany, R (2007). Cancer selective adenoviruses. Mol Aspects Med 28: 42-58.
5. .Lam, JT, Kanerva, A, Bauerschmitz, GJ, Takayama, K, Suzuki, K, Yamamoto, M et al. (2004). Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med 6: 1333-1342.
6. .Zhu, ZB, Lu, B, Park, M, Makhija, SK, Numnum, TM, Kendrick, JE et al. (2008). Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. Int J Oncol 32: 1179-1188.
7. .Spentzos, D, Levine, DA, Ramoni, MF, Joseph, M, Gu, X, Boyd, J et al. (2004). Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700-4710.
8. .Kanerva, A, Bauerschmitz, GJ, Yamamoto, M, Lam, JT, Alvarez, RD, Siegal, GP et al. (2004). A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther 11: 552-559.
9. .Rein, DT, Breidenbach, M, Kirby, TO, Han, T, Siegal, GP, Bauerschmitz, GJ et al. (2005). A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 11: 1327-1335.
10. .Kim, KH, Dmitriev, I, O'Malley, JP, Wang, M, Saddekni, S, You, Z et al. (2012). A Phase I Clinical Trial of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Patients with Recurrent Gynecologic Cancer. Clin Cancer Res 18: 3440-3451.
11. .Vasey, PA, Shulman, LN, Campos, S, Davis, J, Gore, M, Johnston, S et al. (2002). Phase I trial of intraperitoneal injection of the E1B-55-kd-gene- deleted adenovirus ONYX- 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/ refractory epithelial ovarian cancer. J Clin Oncol 20: 1562-1569.
12. .Kimball, KJ, Preuss, MA, Barnes, MN, Wang, M, Siegal, GP, Wan, W et al. (2010). A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 16: 5277-5287.
13. .Tothill, RW, Tinker, AV, George, J, Brown, R, Fox, SB, Lade, S et al.; Australian Ovarian Cancer Study Group. (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
14. .Santala, M, Simojoki, M, Risteli, J, Risteli, L and Kauppila, A (1999). Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5: 4091-4096.
15. .Podhajcer, OL, Benedetti, LG, Girotti, MR, Prada, F, Salvatierra, E and Llera, AS (2008). The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27: 691-705.
16. .Chlenski, A and Cohn, SL (2010). Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 21: 55-65.
17. .Paley, PJ, Goff, BA, Gown, AM, Greer, BE and Sage, EH (2000). Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 78(3 Pt 1): 336-341.
18. .Köbel, M, Turbin, D, Kalloger, SE, Gao, D, Huntsman, DG and Gilks, CB (2011). Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. Int J Gynecol Pathol 30: 366-371.
19. .Porter, PL, Sage, EH, Lane, TF, Funk, SE and Gown, AM (1995). Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 43: 791-800.
20. .Brown, TJ, Shaw, PA, Karp, X, Huynh, MH, Begley, H and Ringuette, MJ (1999). Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol 75: 25-33.
21. .Socha, MJ, Said, N, Dai, Y, Kwong, J, Ramalingam, P, Trieu, V et al. (2009). Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 11: 126-135.
22. .Lopez, MV, Viale, DL, Cafferata, EG, Bravo, AI, Carbone, C, Gould, D et al. (2009). Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses. PLoS ONE 4: e5119.
23. .Jemal, A, Siegel, R, Xu, J and Ward, E (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
24. Bast, RC Jr, Brewer, M, Zou, C, Hernandez, MA, Daley, M, Ozols, R et al. (2007). Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 174: 91-100.
25. Galanis, E, Hartmann, LC, Cliby, WA, Long, HJ, Peethambaram, PP, Barrette, BA et al. (2010). Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70: 875-882.
26. Wang, H, Li, ZY, Liu, Y, Persson, J, Beyer, I, Möller, T et al. (2011). Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.Nat Med 17: 96-104.
27. .Kanerva, A, Mikheeva, GV, Krasnykh, V, Coolidge, CJ, Lam, JT, Mahasreshti, PJ et al. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8: 275-280.
28. .Kanerva, A, Wang, M, Bauerschmitz, GJ, Lam, JT, Desmond, RA, Bhoola, SM et al. (2002). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 5: 695-704.
29. .Hemminki, O, Bauerschmitz, G, Hemmi, S, Lavilla-Alonso, S, Diaconu, I, Guse, K et al. (2011). Oncolytic adenovirus based on serotype 3. Cancer Gene Ther 18: 288-296.
30. Ulasov, IV, Tyler, MA, Rivera, AA, Nettlebeck, DM, Douglas, JT and Lesniak, MS (2008). Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. J Med Virol 80: 1595-1603.
31. Heise, C, Hermiston, T, Johnson, L, Brooks, G, Sampson-Johannes, A, Williams, A et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6: 1134-1139.
32. Sauthoff, H, Pipiya, T, Heitner, S, Chen, S, Bleck, B, Reibman, J et al. (2004). Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Mol Ther 10: 749-757.
33. Stoff-Khalili, MA, Stoff, A, Rivera, AA, Mathis, JM, Everts, M, Wang, M et al. (2005). Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system. Cancer Biol Ther 4: 1203-1210.
34. Rocconi, RP, Zhu, ZB, Stoff-Khalili, M, Rivera, AA, Lu, B, Wang, M et al. (2007). Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol Oncol 105: 113-121.
35. Kirby, TO, Rivera, A, Rein, D, Wang, M, Ulasov, I, Breidenbach, M et al. (2004). A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 10: 8697-8703.
36. Stoff-Khalili, MA, Rivera, AA, Stoff, A, Michael Mathis, J, Rocconi, RP, Matthews, QL et al. (2007). Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer. Int J Cancer 120: 935-941.
37. Stoff-Khalili MA, Rivera AA, Le LP, Stoff A, Everts M, Contreras JL et al. (2006). Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents. Cancer Gene Ther 13: 606-618.
38. AbouEl Hassan MA, Braam SR and Kruyt FA (2006). Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells. Cancer Gene Ther 13: 1105-1114.
39. Seidman, MA, Hogan, SM, Wendland, RL, Worgall, S, Crystal, RG and Leopold, PL (2001). Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol Ther 4: 13-21.
40. Ingemarsdotter, CK, Baird, SK, Connell, CM, Öberg, D, Halldén, G and McNeish, IA (2010). Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 29: 6051-6063.
41. Johnson, M, Huyn, S, Burton, J, Sato, M and Wu, L (2006). Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther 17: 1262-1269.
42. Merron, A, Baril, P, Martin-Duque, P, de la Vieja, A, Tran, L, Briat, A et al. (2010). Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. Eur J Nucl Med Mol Imaging 37: 1377-1385.
43. Sherman-Baust, CA, Weeraratna, AT, Rangel, LB, Pizer, ES, Cho, KR, Schwartz, DR et al. (2003). Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3: 377-386.
44. Kanerva, A, Zinn, KR, Chaudhuri, TR, Lam, JT, Suzuki, K, Uil, TG et al. (2003). Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 8: 449-458.
45. Yang, SW, Cody, JJ, Rivera, AA, Waehler, R, Wang, M, Kimball, KJ et al. (2011). Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Clin Cancer Res 17: 538-549.